Table 2. All grade adverse events of TFD/TPI monotherapy or combined with bevacizumab.
| All grade | TFD/TPI + BEV (n) | TFD/TPI (n) | OR, IV, 95% CI | p value | I 2 |
|---|---|---|---|---|---|
| Anemia | 420 | 409 | 0.73 (0.54; 0.99) | 0.04 | 0% |
| Neutropenia | 420 | 409 | 1.44 (0.92; 2.26) | 0.10 | 39% |
| Thrombocytopenia | 420 | 409 | 1.72 (1.18; 2.50) | <0.01 | 6% |
| Nausea | 515 | 688 | 1.08 (0.67; 1.75) | 0.74 | 74% |
| Vomiting | 409 | 421 | 1.28 (0.88; 1.85) | 0.19 | 0% |
| Diarrhea | 317 | 588 | 1.09 (0.76; 1.55) | 0.65 | 42% |
| Fatigue | 2,789 | 6,909 | 1.12 (0.84; 1.50) | 0.43 | 0% |
| Hypertension | 2,675 | 6,812 | 2.78 (1.56; 4.94) | <0.01 | 59% |
Pooled results of all grade adverse events. n: number of patients analyzed; IV: inverse variance; CI: confidence interval